ProMIS Neurosciences Inc. PMN
ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS' technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $33.4M | $10.6M | $7.9M | $16.1M | $4.6M | — |
| SG&A | $6.8M | $6.2M | $6.4M | $7.3M | $3.7M | — |
| Total operating expenses | $40.2M | $16.8M | $14.3M | $23.4M | $8.3M | — |
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M | -$8.3M | — |
| Pre-tax income | — | $2.8M | -$13.2M | -$18.1M | — | — |
| Income tax | — | $0 | $0 | $0 | — | — |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M | -$9.8M | — |
| EPS, basic | -22.61 | 2.68 | -1.07 | -2.41 | -1.69 | — |
| EPS, diluted | -22.61 | 2.63 | -1.07 | -2.41 | -1.69 | — |
| Shares, diluted (wtd. avg.) | 1.8M | 1.1M | 12.3M | 7.5M | 5.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $6.1M | $13.3M | $12.6M | $5.9M | $16.9M | $806.9K |
| Short-term investments | $33.8K | $33.1K | $32.4K | $31.0K | $33.2K | — |
| Total current assets | $9.2M | $18.9M | $13.6M | $6.9M | $17.7M | — |
| Property, plant and equipment | — | — | — | $321 | $4.7K | — |
| Other intangibles | — | — | — | $20.8K | $27.6K | — |
| Total assets | $9.2M | $18.9M | $13.6M | $6.9M | $17.7M | — |
| Accounts payable | $2.5M | $1.7M | $7.8M | $3.0M | $409.0K | — |
| Total current liabilities | $10.4M | $2.2M | $9.3M | $6.4M | $929.1K | — |
| Long-term debt | — | — | $0 | — | $3.9M | — |
| Total liabilities | $10.4M | $2.4M | $9.9M | $8.3M | $12.1M | — |
| Retained earnings | -$130.4M | -$90.7M | -$93.5M | -$80.3M | -$62.2M | — |
| Total equity | -$1.3M | $16.5M | $3.8M | -$1.3M | $5.7M | -$796.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M | -$9.3M | — |
| Depreciation and amortisation | — | — | $321 | $6.1K | $40.6K | — |
| Stock-based compensation | $857.6K | $825.8K | $271.5K | $487.6K | $515.6K | — |
| Capital expenditure | — | — | — | $2.0K | $6.0K | — |
| Investing cash flow | -$702 | -$693 | -$1.3K | -$2.0K | $94.6K | — |
| Financing cash flow | $20.9M | $27.9M | $17.7M | $6.5M | $25.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-034554.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$9.8M | -$18.1M | -$13.2M | $2.8M | -$39.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |